Older version of tenofovir used as PrEP linked to weight loss
Most switches to Descovy PrEP are probably unnecessary and some may be harmful
People over 50 years old or with existing kidney dysfunction are more likely to get kidney damage when using tenofovir disoproxil-based PrEP
One dose of TAF every three days gets more drug into cells than a daily dose of TDF
Conclusive PrEP study in China paves the way for national provision for gay men
HIV vaccines and immunotherapies “would be further along” if they had the resources of COVID-19, says leading antibody researcher
Studies confirm that hormone levels in trans women are not greatly affected by PrEP, or vice versa
Modelling suggests injectable cabotegravir is far more effective than daily oral PrEP for women
How can HIV research better align with the realities of transgender and gender-diverse people?
